Wegovy pill launches in the US, the first oral GLP-1 approved for obesity

Novo Nordisk launched the Wegovy pill, an oral form of semaglutide, in the United States in January 2026 — the first oral GLP-1 medicine approved for obesity ^[2]. Six months later the company described it as a "best-in-class GLP-1 volume launch," with more than 5 million total prescriptions written since it went on sale ^[1].

Early tracking by the data firm IQVIA found the pill took roughly one-third of new-to-brand prescriptions within eight weeks, with the majority of volume moving through cash-pay channels rather than insurance ^[2]. About two-thirds of the people filling those prescriptions were new to any GLP-1 therapy, which IQVIA read as a sign that convenience and lower prices are expanding the market rather than simply pulling people off injections ^[2].

The prescription numbers kept climbing. For the week ending 17 July 2026, weekly total prescriptions for the Wegovy pill exceeded 265,000, out of roughly 575,000 total weekly prescriptions across the whole Wegovy franchise in the US ^[1]. Measured by new patient starts, Novo says Wegovy remains the market leader among branded obesity drugs in the US ^[1].

That translated into sales of DKK 3,218 million for the Wegovy pill in the second quarter of 2026 and DKK 5,474 million in the first half ^[1]. Total adjusted obesity care sales rose 16% at constant exchange rates in the quarter, to DKK 23,152 million ^[1]. Novo raised its 2026 outlook on the strength of GLP-1 volumes, though adjusted sales growth is still expected to land between 0% and -6% at constant exchange rates ^[1]. CEO Mike Doustdar credited "the continued rapid adoption of Wegovy pill in the US" as a key driver ^[1].

On effectiveness, European regulators approved the Wegovy pill in July 2026 based on the OASIS 4 trial, which showed up to 16.6% mean weight loss ^[1]. That is lower than the up to 20.7% mean weight loss reported in the STEP UP trial that supported the higher-dose 7.2 mg injection, known as Wegovy HD, which launched in the US in April 2026 ^[1].

Why it matters for patients

The practical change is the route: a daily pill instead of a weekly injection, for a condition that typically requires long-term treatment. IQVIA's finding that most early volume flowed through cash-pay channels ^[2] suggests that for many people the pill is being bought outside of insurance coverage. The exact US self-pay prices, the number of participating pharmacies and the telehealth partners involved are not described in the sources available here, so those details cannot be confirmed from this reporting.

A second point worth noting is that the weight-loss figure tied to the pill's European approval — up to 16.6% ^[1] — is not the same as the figure for the highest-dose injection ^[1]. Convenience and cost may come with different expected results, and the sources do not include head-to-head comparisons.

Persistence is also a known weak spot across this drug class. IQVIA reports that how long patients stay on treatment varies widely by brand and by country, and that patients most often cite tolerability problems as the reason they stop ^[2]. Whether pill users stay on treatment longer or shorter than injection users is not yet known from these sources.

Competition is arriving quickly. Eli Lilly's Foundayo (orforglipron), a small-molecule oral GLP-1, reached the US market in April 2026, opening a direct rival to the Wegovy pill ^[2]. IQVIA values the global obesity medicines market at $66 billion in list-price sales in 2025, forecast to reach $92 billion in 2026 ^[2].

What happens next

Novo launched the Wegovy pill in the UAE in June 2026 and the UK in July 2026, with more markets planned in coming quarters ^[1]. The European Medicines Agency approved both the Wegovy pill and the 7.2 mg single-dose pen in July 2026, with an EU rollout of the pen planned for the second half of 2026 ^[1].

Further out, IQVIA expects semaglutide to lose exclusivity across markets including India, China, Brazil, Turkey and Canada starting in 2026, which could shift prices and access ^[2]. Large real-world studies, including SCoMIS and SURMOUNT-REAL, are expected to report by 2029 on whether these drugs reduce cardiovascular events, diabetes and disability at the population level ^[2].